These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 23856292)

  • 1. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
    Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
    Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture.
    Badolo L; Jensen B; Säll C; Norinder U; Kallunki P; Montanari D
    Xenobiotica; 2015 Feb; 45(2):177-87. PubMed ID: 25183402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
    Bucher S; Le Vee M; Jouan E; Fardel O
    J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
    Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
    Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes.
    Jigorel E; Le Vee M; Boursier-Neyret C; Parmentier Y; Fardel O
    Drug Metab Dispos; 2006 Oct; 34(10):1756-63. PubMed ID: 16837569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
    Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
    Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
    Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
    Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.
    Le Vee M; Jouan E; Stieger B; Lecureur V; Fardel O
    PLoS One; 2015; 10(3):e0121232. PubMed ID: 25803276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes.
    Jørgensen L; Van Beek J; Lund S; Schousboe A; Badolo L
    Eur J Pharm Sci; 2007 Feb; 30(2):181-9. PubMed ID: 17174077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures.
    Herzog N; Hansen M; Miethbauer S; Schmidtke KU; Anderer U; Lupp A; Sperling S; Seehofer D; Damm G; Scheibner K; Küpper JH
    Cell Biol Int; 2016 Mar; 40(3):341-53. PubMed ID: 26715207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
    De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
    Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
    Keitel V; Burdelski M; Warskulat U; Kühlkamp T; Keppler D; Häussinger D; Kubitz R
    Hepatology; 2005 May; 41(5):1160-72. PubMed ID: 15841457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.